title: Biomarkers in renal cell carcinoma: what next?
authors.affiliation: Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA. bukow464@sbcglobal.net
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Bukowski
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000188:drug therapy; D015331:Cohort Studies; D006801:Humans; D007680:Kidney Neoplasms / Q000097:blood* / Q000188:drug therapy; D015337:Multicenter Studies as Topic / Q000379:methods; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D014408:Biomarkers, Tumor; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib